Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News C4 Therapeutics Inc CCCC

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on advancing targeted protein degradation science to create a new generation of small-molecule medicines that transform patients’ lives. By leveraging its proprietary Target ORiented ProtEin Degrader Optimizer (TORPEDO) platform, to design and optimize small molecule protein degraders that are active against... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:CCCC)

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

GlobeNewswire 6 days ago

C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen

GlobeNewswire 9 days ago

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

GlobeNewswire 10 days ago

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

GlobeNewswire September 3, 2024

C4 Therapeutics to Participate in Upcoming September Investor Conferences

GlobeNewswire August 29, 2024

C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation

GlobeNewswire August 14, 2024

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire August 1, 2024

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

GlobeNewswire July 16, 2024

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

GlobeNewswire July 8, 2024

Opinion & Analysis (NDAQ:CCCC)

No current opinion is available.

Bullboard Posts (NDAQ:CCCC)

C4 Therapeutics Presents Monotherapy Data Demonstrating Proo

News; $CCCC C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From...
whytestocks - 6 days ago

CCCC C4 Therapeutics up more than 20% on annual report filin

JUST IN: $CCCC CCCC C4 Therapeutics up more than 20% on annual report filing2024-02-22 14:04:23 ET DENVER, Colo., Feb 22, 2024...
whytestocks - February 22, 2024

x

[img]http://http://cdn.business2community.com/wp-content/uploads/2014/11/image41-600x400.jpg[/img]
neinstein - July 12, 2016